Status:
COMPLETED
Anderson-Fabry Disease in Chronic Kidney Disease Patients Not on Renal Replacement Therapy
Lead Sponsor:
Klinikum Wels-Grieskirchen
Collaborating Sponsors:
Genzyme, a Sanofi Company
Conditions:
Focus of Study: Prevalence of Fabry Disease in CKD Population
Eligibility:
All Genders
18-85 years
Brief Summary
Anderson-Fabry disease is a rare X-linked lysosomal storage disorder due to the deficiency of alfa-galactosidase A (AGAL). The subsequent accumulation of glycosphingolipids may lead to to cardiac, ren...
Eligibility Criteria
Inclusion
- Chronic kidney disease KDOQI stage 1-5
- Informed consent
Exclusion
- Patients already on renal replacement therapy
- Not willing to participate
Key Trial Info
Start Date :
October 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
4353 Patients enrolled
Trial Details
Trial ID
NCT00728364
Start Date
October 1 2008
End Date
December 1 2011
Last Update
April 12 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Klinikum Wels-Grieskirchen
Wels, Upper Austria, Austria, A-4600